



# Genome-wide polygenic risk scores for hypertensive disease during pregnancy identify women at risk for long-term cardiovascular disease

Seung Mi Lee<sup>1,2</sup>, Manu Shivakumar<sup>2</sup>, Yonghyun Nam<sup>2</sup>, Brenda Xiao<sup>2</sup>, Jae-Seung Yun<sup>2,3</sup>, Sang-Hyuk Jung<sup>2</sup>, Eun Kyung Choe<sup>2,4</sup>, Dokyoon Kim<sup>2</sup> <sup>1</sup>Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Korea; <sup>2</sup>Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, USA; <sup>3</sup>Department of Internal Medicine, Catholic University College of Medicine, Korea; <sup>4</sup>Department of Surgery, Seoul National University Hospital Healthcare System Gangnam Center, Korea

## **Background & Aims**

• Previous studies suggest that hypertensive disease during pregnancy (HDP) increase the risk of long-term cardiovascular disease later in life, and clinical guidelines recommend including HDP as important female specific factor in risk assessment.

• However, it has not been issued whether genetic trait for HDP determines the development of subsequent cardiovascular disease.

## **Methods**

- From the UK biobank, we included unrelated Caucasian women with at least one live birth and available genetic data.
- HDP-PRS was calculated by LDpred using the summary statistics from FinnGen, another large-scale biobank.
- Subjects were divided according to the genetic risk categorized by HDP-PRS and were evaluated for incident cardiovascular disease.



 In the current study, we developed polygenic risk scores for HDP (HDP-PRS) from genome-wide associated study (GWAS) data and evaluated its impact on long-term cardiovascular outcome.

	Low PE-PRS (≤75p)	High PE-PRS (>75p)	<b>P-value</b>
	(n = 124,030)	(n = 41,303)	
Baseline characteristics at enrollment			
Age (years)	$57.2 \pm 7.7$	$57.2 \pm 7.6$	0.664
BMI	$27.0 \pm 5.0$	$27.3 \pm 5.2$	<0.001
Age at first live birth	$25.4 \pm 4.5$	$25.2 \pm 4.5$	<0.001
Number of liver births	$2.2 \pm 0.9$	$2.2 \pm 0.9$	0.658
Mean duration between first birth and enrollment	$32.2 \pm 9.5$	$32.3 \pm 9.5$	0.024
Ever smoking	50583 (40.8%)	16932 (41.0%)	0.452
Use of medication			
- Aspirin	12439 (10.0%)	4486 (10.9%)	<0.001
<ul> <li>Anti-hypertensive</li> </ul>	22507 (18.1%)	9111 (22.1%)	<0.001
<ul> <li>Cholesterol lowering agent</li> </ul>	17213 (13.9%)	6327 (15.3%)	<0.001
Blood pressure at enrollment			
<ul> <li>Systolic blood pressure</li> </ul>	135.8 ± 19.3	137.3 ± 19.3	<0.001
<ul> <li>Diastolic blood pressure</li> </ul>	80.5 ± 9.9	81.4 ± 9.9	<0.001
Prevalent comorbidity at baseline			
Hypertension	30225 (24.4%)	12015 (29.1%)	<0.001
Diabetes	4086 (3.3%)	1618 (3.9%)	<0.001
Dyslipidemia	14509 (11.7%)	5296 (12.8%)	<0.001
Data are presented as proportion (%) or mea	$n \pm standard deviation.$		
Data are presented as proportion (%) or mea Abbreviations: BMI, body mass index; PE, p	n ± standard deviation. preeclampsia to Figure 2. P history c	Prevalent Hypertens	sion by t RS score
Data are presented as proportion (%) or mea Abbreviations: BMI, body mass index; PE, p Figure 1. Risk of HDP according polygenic risk score	n ± standard deviation. preeclampsia <b>to</b> Figure 2. P history c	Prevalent Hypertens of HDP and HDP-PF	sion by t RS score
Data are presented as proportion (%) or mea Abbreviations: BMI, body mass index; PE, p Figure 1. Risk of HDP according polygenic risk score HDP (p<0.001 for trend) *(OR 1.24)	n ± standard deviation. preeclampsia Figure 2. P history c	Prevalent Hypertens of HDP and HDP-PF	sion by f RS score
Data are presented as proportion (%) or mea Abbreviations: BMI, body mass index; PE, p Figure 1. Risk of HDP according polygenic risk score HDP (p<0.001 for trend) *(OR 1.24)	n ± standard deviation. preeclampsia Figure 2. P history c	Prevalent Hypertens of HDP and HDP-PF	sion by f RS score
Data are presented as proportion (%) or mea Abbreviations: BMI, body mass index; PE, p Figure 1. Risk of HDP according polygenic risk score	n ± standard deviation. reeclampsia Figure 2. P history c	Prevalent Hypertens of HDP and HDP-PP	sion by f RS score
Data are presented as proportion (%) or mea Abbreviations: BMI, body mass index; PE, p Figure 1. Risk of HDP according polygenic risk score HDP (p<0.001 for trend) *(OR 1.24) *(OR 1.24)	n ± standard deviation. reeclampsia Figure 2. P history c	Prevalent Hypertens of HDP and HDP-PP	sion by a RS score
Data are presented as proportion (%) or mea Abbreviations: BMI, body mass index; PE, p Figure 1. Risk of HDP according polygenic risk score	n ± standard deviation. preeclampsia Figure 2. P history c	Prevalent Hypertens of HDP and HDP-PE	sion by t RS score
Data are presented as proportion (%) or mea Abbreviations: BMI, body mass index; PE, p Figure 1. Risk of HDP according polygenic risk score	n ± standard deviation. breeclampsia Figure 2. P history c	<section-header></section-header>	sion by f RS score

Figure 3. Survival analysis according to polygenic risk score for HDP and the history of HDP by Cox regression analyses

#### **Coronary artery disease**



#### **Myocardial infarction**



High PRS: HR 1.09 (1.015-1.162, p<sup>2</sup>= 0.017) \*p, After adjustment for age, BMI, smoking, prevalent hypertension/DM/dyslipidemia, HDP

#### Heart failure



High PRS: HR 1.18 (1.0586-1.308, p<sup>2</sup>= 0.002) \*p, After adjustment for age, BMI, smoking, prevalent hypertension/DM/dyslipidemia, HDP High PRS: HR 1.23 (1.107-1.372, p<sup>2</sup><0.001)</li>
\*p, After adjustment for age, BMI, smoking, prevalent hypertension/DM/dyslipidemia, HDP

#### Aortic stenosis



High PRS: HR 1.23 (1.011-1.486, p<sup>2</sup>= 0.038)
\*p, After adjustment for age, BMI, smoking, prevalent hypertension/DM/dyslipidemia, HDP

### Figure 4. Hazard ratio of each cardiovascular outcomes by Cox regression analyses



 This study provides evidence on the informative value of HDP-PRS in the prediction of long-term cardiovascular outcomes later in life.

Conclusion

 The application of PRS information for risk assessment and medical interventions needs to be evaluated in further studies.

